argenx SE (NASDAQ:ARGX) Position Cut by Candriam S.C.A.

Candriam S.C.A. lessened its stake in argenx SE (NASDAQ:ARGX - Free Report) by 6.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 48,210 shares of the company's stock after selling 3,208 shares during the quarter. Candriam S.C.A. owned about 0.08% of argenx worth $29,649,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ARGX. Raymond James Financial Inc. purchased a new position in shares of argenx in the fourth quarter valued at $43,543,000. Assetmark Inc. lifted its holdings in argenx by 11.3% in the 4th quarter. Assetmark Inc. now owns 8,648 shares of the company's stock worth $5,319,000 after buying an additional 879 shares in the last quarter. J.Safra Asset Management Corp boosted its position in argenx by 123.8% in the 4th quarter. J.Safra Asset Management Corp now owns 273 shares of the company's stock valued at $169,000 after buying an additional 151 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of argenx by 21.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,214 shares of the company's stock valued at $2,592,000 after acquiring an additional 755 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of argenx by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock valued at $234,000 after acquiring an additional 20 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Price Performance

NASDAQ:ARGX traded down $23.21 during midday trading on Monday, reaching $571.00. 548,019 shares of the company traded hands, compared to its average volume of 283,470. The firm has a market capitalization of $34.69 billion, a price-to-earnings ratio of -648.86 and a beta of 0.59. The company has a fifty day moving average price of $641.45 and a 200 day moving average price of $594.49. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities research analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ARGX shares. HC Wainwright increased their price target on argenx from $717.00 to $720.00 and gave the company a "buy" rating in a report on Friday, February 28th. Robert W. Baird increased their target price on argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a research note on Tuesday, March 4th. William Blair restated an "outperform" rating on shares of argenx in a research note on Friday, February 28th. JMP Securities upped their price target on shares of argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Finally, Guggenheim raised their price objective on shares of argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a report on Monday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.